All News

Biologic.choice.MD_.jpeg (keep)

Treatment Sequences Define Subphenotypes in RA Patients

Jack Cush, MD

An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time. 

Read Article
cost.price_.drugs_.pills_.jpg

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?

Jack Cush, MD

Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?

Read Article
Cancer.risk_.jpg

Cancer Risk From RA, Not the Drugs

Jack Cush, MD

While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.

Read Article
RheumNow Podcast square

How Often Do You Monitor MTX? (6.16.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. 

Read Article
depression oh no HA

Why Depression Screening Should be Mandatory at Each Visit

Jack Cush, MD

Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015. 

Read Article
RA.Ow02.jpg

High Mortality Rates with Depression in Rheumatoid Arthritis

Jack Cush, MD

A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA).  

Read Article
biosim.sign_.jpg

Biosimilars Match Biologic Originators in Rheumatoid Arthritis

Jack Cush, MD

A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

EULAR 2023 Notes from Milan (6.09.2023)

Jack Cush, MD

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Read Article
Watch: Should you Assess Rheumatoid Factor Serially? Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy. https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd

Links:

Dr. John Cush RheumNow ( View Tweet)
275 early RA pts and after 2 years, 32% reported unacceptable pain (UP). Predictors of UP best seen at 3 mos FUV (not baseline) and included #Tender Jts (not swollen), overall pain, patient global assessment, and HAQ. https://t.co/Zlv3919Ucz https://t.co/1K1zPvhUYi

Links:

Dr. John Cush RheumNow ( View Tweet)
Biosimilars Match Biologic Originators in RA A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA. https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/fA6gzta5rx https://t.co/mGdzTqjEr7

Links:

Dr. John Cush RheumNow ( View Tweet)
High Mortality Rates with Depression in Rheumatoid Arthritis A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA). https://t.co/R2MB4bs0Hr https://t.co/rWIfHmBqr8

Links:

Dr. John Cush RheumNow ( View Tweet)
TNR- Rheumatoid Arthritis - Decisive Therapeutics Replay of this RA pod from RheumNow Live 2023, recorded on March 18, 2023 https://t.co/RyyKQFDrT5 https://t.co/ZHjJRzHJ0Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Karolinska SARA (secretory antibodies in RA) study of 132 RA pts found salivary IgA anti-RgpB Abs signif higher in RA than (p = 0.022), & were assoc w/ disease activity (p = 0.036), but not with periodontitis or serum IgG ACPA. https://t.co/4uul4b5Fhg https://t.co/R5WVCyjc3B

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/6OVZhkTdGc https://t.co/3VHhI7nfQm

Links:

Dr. John Cush RheumNow ( View Tweet)
Assessing CV Risk in Inflammatory Arthritis: Which Score? Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/qlJ9iMwrip @AurelieRheumo https://t.co/Yh2siy6555

Links:

Dr. John Cush RheumNow ( View Tweet)
Postpartum Depression in RA Dr. Jonathan Kay discusses abstract POS0206-HPR at EULAR 2023 in Milan, Italy. https://t.co/dzUMIia8Q6 https://t.co/IjeEvz8Cab

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular Risks Dr. Antoni Chan discusses abstracts OP0132, POS0831, and OP0133 presented at EULAR 2023 in Milan, Italy. https://t.co/ApLaPf7uKP https://t.co/nbZgwIlHyb

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×